You might expect a future rocket crash to scare customers away from Virgin Galactic -- but you might be wrong.
Don't look now, but Rocket Lab may have a new rival -- and SpaceX, too.
You can justify almost any valuation with a 100%-plus growth rate, and Boston Omaha has just that.
First some HEXO shares go on sale -- then they all do.
UBS ups its price target by 50%.
The grocer's stock wilts under the heat of an analyst downgrade.
A big endorsement from J.P. Morgan boosts shares.
The healthcare solutions company sells a division, and collects a bit of cash.
Virgin Galactic gets a COO...and that's all the news that's fit to print.
Investors cheer the prospect of a full frontal attack on Align Technology's business.
Barclays' double downgrade cratered the share price.
Two new hires spark hope for a revival in sales growth.
We're No. 3! We're No. 3!
Earnings are on deck. What will Virgin say?
Dunkin' Brands will be bringing the company's faux-meat sausage to the menu.
New announcement propels 3D into the realm of biotech.
It won't be a huge tunnel -- but a company's gotta start somewhere.
Two defense contractors could be hurt a bit. But one company stands to benefit a lot.
By 2025, SpaceX could be earning $22 billion a year.
Maxar managed to sell 20% of its revenue for 80% of its market cap. Hurray?